19 novGenome-wide expression profiling of human Lymphoblastoid Cell Lines (LCL) discover novel SSRI antidepressants response biomarkers19 nov 2013
David Gurwitz National Laboratory for the Genetics of Israeli populations, Université de Tel Aviv, Israel
sur invitation de Marie-Anne Loriot (UMR-S775)
donnera une conférence au Centre des St-Pères (salle P436) à 13h30
"Genome-wide expression profiling of human Lymphoblastoid Cell Lines (LCL) discover novel SSRI antidepressants response biomarkers"
Biographie en anglais de Gurwitz D, Tel Aviv University, IL
David Gurwitz (PhD) directs the National Laboratory for the Genetics of Israeli Populations (NLGIP) at the Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel. The NLGIP is the national biobank of Israel, featuring a collection of human lymphoblastoid cell lines and DNA samples representing the ethnic diversity of the Jewish and Arab populations of Israel. DNA samples and cell lines from this repository were constructive in scores of international research projects in various fields of human biology and medicine, including the pharmacogenomics of drug metabolizing enzymes, drug transporters, and drug target genes. Dr Gurwitz is an affiliate member of the PGRN and has co-authored the European Commission’s 2006 report on “Pharmacogenetics and pharmacogenomics: state-of-the- art and potential socio-economic impact in the EU”. He is senior editor of Pharmacogenomics and associate editor of Drug Development Research and additional journals. His current research is focused on applying human lymphoblastoid cell lines for the discovery of drug response biomarkers.